APA (7th ed.) Citation

Fujino, T., Okamoto, H., Nishiyama, D., Hayata, H., Sasaki, N., Kobayashi, T., . . . Fuchida, S. (2025). Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: A multicenter retrospective study. Leukemia & Lymphoma, 66(8), 1425. https://doi.org/10.1080/10428194.2025.2483390

Chicago Style (17th ed.) Citation

Fujino, Takahiro, et al. "Real-world Data of Polatuzumab Vedotin with Bendamustine and Rituximab for Japanese Relapsed and Refractory DLBCL: A Multicenter Retrospective Study." Leukemia & Lymphoma 66, no. 8 (2025): 1425. https://doi.org/10.1080/10428194.2025.2483390.

MLA (9th ed.) Citation

Fujino, Takahiro, et al. "Real-world Data of Polatuzumab Vedotin with Bendamustine and Rituximab for Japanese Relapsed and Refractory DLBCL: A Multicenter Retrospective Study." Leukemia & Lymphoma, vol. 66, no. 8, 2025, p. 1425, https://doi.org/10.1080/10428194.2025.2483390.